As of Thursday, December 18, Century Therapeutics, Inc.’s IPSC share price has surged by 12.35%, which has investors ...

Dublin, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2034" report has been added to ResearchAndMarkets.com's offering. This ...

SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid pain therapies, unveiled new data today on a novel approach to chronic pain management and joint tissue preservation.

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks ...

DUBLIN--(BUSINESS WIRE)--The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2025" report has been added to ResearchAndMarkets.com's offering. Since the ...

Left ventricular non-compaction (LVNC) is the third most prevalent cardiomyopathy in children and its pathogenesis has been associated with the developmental defect of the embryonic myocardium. We ...

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks ...

SereNeuro Therapeutics revealed promising results for SN101, a first-in-class iPSC-derived therapy designed to treat chronic ...

In this interview, we speak to representatives of Axol Bioscience about their human iPSC-derived cells and how they have the potential to revolutionize the field of neurodegenerative disease. Liam ...

IPSC was founded in 1977 and has grown rapidly over the past 30 years. With over 800 employees, IPSC is a multi-divisional firm. IPSC installs high quality security systems for residential and ...